TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03705702

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Education Program
Description: The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education, which will include information about the pathophysiology of asthma, medication and peak flow meter instructions, self-monitoring techniques, environmental control techniques and avoidance strategies. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active and maintain a healthy lifestyle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Program
Description: The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education, which will include information about the pathophysiology of asthma, medication and peak flow meter instructions, self-monitoring techniques, environmental control techniques and avoidance strategies. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active and maintain a healthy lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention
Description: The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting 40 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own PA data and the behavioural change stage, an individual action plan will be established with realistic goals to increase PA. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time. Techniques such as weekly goal-setting, motivational interviewing, activity tracker vibration instructions, self-management, positive reinforcement, relapse prevention and strategies to overcome barriers will be included.
Study: NCT01321034

Intervention type: DRUG
Group type: OTHER
Intervention: Niacin/Laropiprant
Description: 1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
Study: NCT02007902

Intervention type: OTHER
Intervention: Evaluation of the relationship plasma protein levels - neonatal hemodynamics
Description: * Patient inclusion at birth~* Total plasma protein values measurement on cord blood sample at birth~* Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler~* Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth~* Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 \[regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy\] will be monitored over 24 hours after birth.
Study: NCT01895985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod
Study: NCT04379505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring gantry kV-CBCT combined with linear accelerator (Halcyon)
Description: -Varian Medical Systems is the manufacturer
Study: NCT04979481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRAVE
Description: The BRAVE campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The role model videos (1-3 minutes each) featured relatable characters experiencing and addressing violent behavior, alcohol misuse, and suicidality (through the eyes of a perpetrator, an intimate partner violence survivor, and a peer bystander), intended to demonstrated important coping and help-seeking skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEM
Description: The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The series promoted STEM career pathways and highlighted Native professionals in Science, Technology, Engineering, Math, and Medical careers.
Study: NCT02987010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH305
Description: Isocitrate Dehydrogenase 1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH305
Description: Isocitrate Dehydrogenase 1 inhibitor
Study: NCT03236597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill desk
Description: A standing height desk with a treadmill attached.
Study: NCT02076100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Study: NCT03692429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYAD-101
Description: Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYAD-101
Description: Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 5-FU, leucovorin and oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-FU, leucovorin and irinotecan
Study: NCT02446691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY
Description: Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
Study: NCT00789503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread fortified with vitamin D3 and calcium
Description: Bread fortified with vitamin D3 (5000 IU per bun) and calcium
Study: NCT03143361

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: All surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
Study: NCT02048800

Intervention type: DRUG
Intervention: Treosulfan
Description: Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged \< 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged \> 12 months)
Study: NCT00954681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Quetiapine treatment from 25 mg daily to 300 mg twice daily
Study: NCT04080726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601
Description: Oral esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1705
Description: Oral Nexium Tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601 Placebo
Description: Oral Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1705 Placebo
Description: Oral Placebo
Study: NCT03241095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMT (Osteopathic Manipulative Treatment)
Description: The co-hort will receive OMT. Each participant will perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. This co-hort will then be evaluated by the physician and be given OMT.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The co-hort participants will each perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. Theythen be given a sham OMT procedure.
Study: NCT03957785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlterG Treatment
Description: All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlterG Treatment
Description: All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlterG Treatment
Description: All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.
Study: NCT01401322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 50 mg; po
Study: NCT01975558

Intervention type: BIOLOGICAL
Intervention: Sampling at baseline, one week after baseline, two weeks after baseline

Intervention type: BIOLOGICAL
Intervention: Sampling at baseline, during radiotherapy and after

Intervention type: BIOLOGICAL
Intervention: Sampling at baseline, during radiotherapy and after
Study: NCT02389959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: 4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
Study: NCT02902835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BUP_FAST
Description: Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to treatment
Description: Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
Study: NCT04379505

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Quad shot radiation
Description: Treatment of each cycle should ideally take place on two consecutive days. Allowing for holidays, weekends, and other scheduling issues or unexpected delays, treatment may be completed within five calendar days.
Study: NCT03593226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGI-134
Description: AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
Study: NCT04048902

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pilates and Shortwave placebo
Description: Pilates exercises and application of the device without produce thermal effects

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pilates and Shortwave active
Description: Pilates exercises and application of the device producing thermal effects
Study: NCT03652727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG-EM Guidance
Description: ECG-EM method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) \[CE marked device, C. R. Bard, Inc.\].~At the end of procedure, a chest x-ray is performed to assess the PICC position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX Guidance
Description: FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning.~At the end of procedure, a chest x-ray is performed to assess the PICC position
Study: NCT01476449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
Study: NCT02412787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase-IT
Description: Participants will receive 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (\>8 months to 30 months of age) and 10 mg (\>30 months to 3 years of age).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elaprase
Description: Participants will receive intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
Study: NCT00085787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-142886, MEK inhibitor; oral
Description: Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
Study: NCT04211662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Multidimensional Intervention. the tailored intervention will be implemented through 6 months using a multidimensional approach (skill building, psychoeducation and peer support).
Description: Skill-building can be defined as training the family caregivers the following skills (1) hands-on training in such skills as positioning, transferring and mobility techniques and assistance with activities of daily living; (2) coping strategies and stress management (3) communicating with healthcare professionals. Psycho-education is teaching and provision the family caregivers the knowledge and information regarding stroke (stroke definition, types of stroke, risk factors, prevention of recurrent stroke, medication management, stroke complications and measures for prevention and management of these complications). Besides, family caregivers will be taught and given the knowledge and information regarding managing stroke survivors' emotions and behaviors. Peer support can be defined as engaging the family caregivers of stroke survivors in interactions with their peers for support and exchanging advices and experiences.
Study: NCT04994353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No supplementation
Description: 1st Week: No supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Performance (HP) Inulin
Description: 2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isomalto-oligosaccharide (IMO)
Description: 3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination HP-Inulin and IMO
Description: 4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).~Ingredients: 20 gram IMO-HP Inulin Mix diluted with 100 ml distilled water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dextrose solution
Description: 5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: 6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
Study: NCT01903824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-26401
Description: CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-26401
Description: CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-26401
Description: CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride
Description: Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: modafinil 200 mg tablet, over-encapsulated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebos formulated to match each active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebos formulated to match each active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebos formulated to match each active drug
Study: NCT01978327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2647544
Description: repeat dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2647544
Description: repeat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug-drug interaction
Description: drug-drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug-drug interaction
Description: drug-drug interaction
Study: NCT05890859

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DXA scan
Description: The patients will undergo 5 DXA scans fro pre- to post treatment

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical testing
Description: The patients will undergo tests for maximal muscle strength and functional performance before and after treatment
Study: NCT01575600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative lactated Ringer's solution
Description: After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative lactated Ringer's solution
Description: After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
Study: NCT01720277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD Fluzone Vaccine
Description: Nursing home residents over 65 years are allocated to receive high dose trivalent vaccine. Residents under 65 years are provided standard dose trivalent vaccine (TIV).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SD Fluzone Vaccine
Description: Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
Study: NCT04004104

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Upright Exercise
Description: Exercise is generally performed in the upright position.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Supine Exercise
Description: Since HPS patients with orthodeoxia experience an improvement in their symptoms and oxygen levels when supine, the intervention will involve them performing exercise in the supine position.
Study: NCT02146404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoglycemia
Description: Blood glucose levels will be kept at \~3.0 mmol/l

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: euglycemia
Description: Blood glucose levels will be kept at \~5.0 mmol/l
Study: NCT02421692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Rehabilitation
Description: Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
Study: NCT03499808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02889068

Intervention type: OTHER
Intervention: Blood sample
Study: NCT01204034

Intervention type: DRUG
Group type: OTHER
Intervention: Inuvair
Description: 6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
Study: NCT00781846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: oral tablets, daily for 5 days/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: oral tablets, daily for 5 days/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: oral tablets, daily for 5 days/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV infusion